How LRC-TriCEPS Identified LPHN2 as the Receptor for LRG1
Discover how LRC-TriCEPS identified LPHN2 as the receptor for LRG1 and enabled new research into diabetic vascular and nerve repair pathways.
Discover how LRC-TriCEPS identified LPHN2 as the receptor for LRG1 and enabled new research into diabetic vascular and nerve repair pathways.
Damaris Bausch-Fluck et al. just published a cell surface protein atlas from 41 human and 31 mouse cell types. If gives a fascinating insight in the surfaceome, where the cell interacts with its surroundings and provides targets for many pharmaceutical interventions.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0121314
According to a recent comment in Nature by Andrew Bradbury, Andreas Plückthun, and co-signed by 110 other scientist protein-binding reagents (e.g. antibodies) should be defined by their sequences and produced as recombinant proteins to save money and improve reproducibility of published studies (1). Additionally, this will lead to an increased reliability of antibodies used. Already in 2008 a study showed that only half of the routinely used commercial antibodies recognize their specified target only(2). The problem of unspecific antibodies used in experiments is repeatedly the reason for retraction of scientific papers. Recently, a paper published in Nature Cell Biology dealing about>INS regulation had to be retracted because of unspecific antibodies(3). Clearly, the rising doubt in antibody specificity needs to be tackled with appropriate test experiments.
At Dualsystems Biotech AG we have the ability to test antibodies targeting extracellular epitopes in vivo. The CaptiRECTM service offered is able to identify the target proteins of antibodies. In a LC-MS/MS based approach we identify the main target and if present off-targets of antibodies. The service offered can be applied to established cell lines, primary cells or tissue. In addition to antibodies, other ligands such as peptides can be used to determine their target(4, 5). For further information about testing the specificity of your antibodies or identifying orphan ligand-receptor interactions using CaptiRECTM please contact